PDL BioPharma PE Ratio 2010-2020 | PDLI

Current and historical p/e ratio for PDL BioPharma (PDLI) from 2010 to 2020. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. PDL BioPharma PE ratio as of January 27, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

PDL BioPharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2020-12-30 2.47 0.00
2020-12-31 2.47 $-1.17 0.00
2020-06-30 2.91 $-1.33 0.00
2020-03-31 2.82 $-0.85 0.00
2019-12-31 3.25 $-0.48 0.00
2019-09-30 2.16 $0.18 12.00
2019-03-31 3.72 $-0.42 0.00
2018-12-31 2.90 $-0.46 0.00
2018-09-30 2.63 $-0.42 0.00
2018-06-30 2.34 $-0.64 0.00
2018-03-31 2.94 $0.26 11.31
2017-12-31 2.74 $0.64 4.28
2019-06-30 3.14 $0.53 5.92
2017-09-30 3.39 $0.51 6.65
2017-06-30 2.47 $0.45 5.49
2017-03-31 2.27 $0.09 25.22
2016-12-31 2.12 $0.39 5.44
2016-09-30 3.35 $1.06 3.16
2016-06-30 3.14 $1.40 2.24
2016-03-31 3.28 $1.84 1.78
2015-12-31 3.44 $2.00 1.72
2015-09-30 4.69 $1.71 2.74
2015-06-30 5.82 $1.90 3.07
2015-03-31 6.23 $1.95 3.19
2014-12-31 6.68 $1.89 3.54
2014-09-30 6.36 $1.96 3.24
2014-06-30 8.11 $1.71 4.74
2014-03-31 6.85 $1.81 3.79
2013-12-31 6.84 $1.73 3.96
2013-09-30 6.35 $1.68 3.78
2013-06-30 6.04 $1.64 3.68
2013-03-31 5.60 $1.54 3.64
2012-12-31 5.29 $1.47 3.60
2012-09-30 5.68 $1.37 4.14
2012-06-30 4.79 $1.33 3.60
2012-03-31 4.49 $1.19 3.77
2011-12-31 4.27 $1.15 3.72
2011-09-30 3.73 $0.73 5.12
2011-06-30 3.85 $0.69 5.58
2011-03-31 3.71 $0.61 6.08
2010-12-31 3.88 $0.51 7.61
2010-09-30 3.28 $0.86 3.81
2010-06-30 3.20 $0.90 3.56
2010-03-31 3.54 $1.06 3.34
2009-12-31 3.64 $1.14 3.20
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.000B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00